Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins

Summary

The release of circulating tissue factor pathway inhibitor (TFPI) into plasma by heparins is thought to contribute to their overall anti-thrombotic activity. In the presented study in healthy volunteers, we measured the heparin-induced increase of circulating total and free TFPI antigen and the aXa- and aIIa activity after subcutaneous (s.c.) injection of 9000 aXa-U of four different heparins: unfractionated heparin (UFH) (13.0 kDa), a medium molecular weight (MW) heparin with a narrow MW range (HF) (10.5 kDa), certoparin (6.0 kDa) and enoxaparin (4.5 kDa). Based on the administration of equi-active aXa doses, certoparin induced the highest increase in total TFPI determined as AUC (p <0.01). The lowest effect was observed for UFH (p <0.0001). However, the AUC of released free TFPI significantly increased in the order: enoxaparin < UFH < certoparin < HF, showing MW dependency with the exception of UFH. Comparing the effects of equi-gravimetric heparin doses, the MW dependency becomes even more pronounced. The mismatch of UFH may be due to its poor bioavailability, which becomes obvious from its low ex vivo aXa activity. In contrast to the TFPI releasing potency, the ex vivo aXa activity continuously decreased with increasing MW. Although the ex vivo aIIa activity of the heparins increased in the same order like the release of free TFPI, there was no clear correlation. This is attributed to the fact that the aIIa activity of heparin is not only dependent on the MW, but, in contrast to its TFPI releasing effect, also on the percentage of material with high affinity to AT. In conclusion, besides the aXaand aIIa activity, the TFPI releasing effect of heparins is an additional parameter of their individual pharmacological profile.

Keywords

TFPI - heparin - low molecular weight heparin - pharmacokinetics - pharmacological profile

• References

• 1 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
• 2 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
• 3 Valentin S, Ostergaard P, Kristensen H, Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin [letter]. Blood Coagul Fibrinolysis 1992; 3: 221-2.
• 4 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23 (Suppl. 01) 103-6.
• 5 Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 879-85.
• 6 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439-49.
• 7 Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordoy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro . Thromb Res 1997; 85: 413-25.
• 8 Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, Saito H. Human ryudocan from endothelium-like cells binds basic fibro-blast growth factor, midkine and tissue factor pathway inhibitor. J Biol Chem 1996; 271: 5914-20.
• 9 Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thromb Res 1996; 84: 267-78.
• 10 Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994 15 (75) 173-83.
• 11 Jeske W, Lormeau JC, Callas D, Iqbal O, Hoppensteadt D, Fareed J. Antithrombin III, affinity dependence on the anticoagulant, antiprotease and tissue factor pathway inhibitor actions of heparins. Semin Thromb Hemost 1995; 21: 193-200.
• 12 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439-49.
• 13 Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb Haemost 1998; 80: 692-5.
• 14 Alban S, Schauerte A, Hoppensteadt D, Fu K, Yang L, Iqbal O, Fareed J, Franz G. Increase of total and especially free TFPI plasma concentration after i.v. application of anticoagulant β-1,3-glucan sulfates. Thromb Haemost 1997; Suppl: PS1676.
• 15 Hoppensteadt DA, Jeske W, Fareed J, Bermes Jr EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6 (Suppl. 01) S57-64.
• 16 Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-85.
• 17 Hansen JB, Sandset PM, Huseby KR, Huseby NE, Bendz B, Ostergaard P, Nordoy A. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-46.
• 18 Witt I, Beeser H, and Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen. Lab Med 1995; 19: 143-5.
• 19 Alban S, Gastpar R. In vitro influence of heparin on plasma total and free tissue factor pathway inhibitor (TFPI) as measured by ELISA. Pharm Pharmacol Lett 2000; 10: 51-4.
• 20 Gibaldi M, Perrier D. Pharmacokinetics. 2nd Edition. Marcel Dekker; New York, Basel: 1992
• 21 Rowland M, Tozer TN. In: Clinical Pharmacokinetics. Concepts and Applications. Lea and Febiger; Philadelphia, London: 1989. pp 459-61.
• 22 Generica, Version 2.0, Prof. Dr. R. Zincke Coesfeld, Germany 1989.
• 23 Albada J, Nieuwnhuis HK, Sixma JJ. Pharmacokinetics of Standard and Low Molecular Weight Heparin. In: Heparin: Chemical and Biological Properties, Clinical Applications. Lane DA, Lindahl U. eds. London: Edward Arnold; 1989: 417-31.
• 24 Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993; 4: 713-20.
• 25 Béguin S, Welzel D, Al Dieri A, Hemker HC. Conjectures and Refutations on the mode of action of heparins. Haemostasis 1999; 29: 170-8.
• 26 Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 1993; 70: 942-5.
• 27 Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thromb Res 1997 15 (86) 343-8.
• 28 Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DP. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-33.
• 29 Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze Jr GJ, Schwartz AL. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo . J Biol Chem 1995; 270: 24800-43.